Nektar Therapeutics (NKTR) Short term Debt (2011 - 2020)
Nektar Therapeutics' (NKTR) quarterly Short term Debt came in at $254.1 million in Q1 2020, little changed quarter-over-quarter from $252.9 million in Q4 2019.
Nektar Therapeutics (NKTR) Short term Debt (2011 - 2020) Analysis & Trends
Nektar Therapeutics' Short term Debt history runs 5 years deep, the most recent figure standing at $254.1 million for Q1 2020.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $254.1 million in Q1 2020; TTM through Mar 2020 was $254.1 million, a N/A change from a year earlier, with the FY2019 full-year figure at $252.9 million, changed N/A from the prior year.
- Short term Debt steadied at $254.1 million in Q1 2020 per NKTR's latest filing, from $252.9 million in the prior quarter.
- Across five years, Short term Debt topped out at $254.1 million in Q1 2020 and bottomed at $252.9 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Nektar Therapeutics | 2.04 Bn | 1.48 Bn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 254.14 Mn |
| Dec 31, 2019 | 252.89 Mn |
| Sep 30, 2015 | 125.00 Mn |
| Mar 31, 2012 | 214.96 Mn |
| Dec 31, 2011 | 214.96 Mn |
| Sep 30, 2011 | 214.96 Mn |